SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...

RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an ...

Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...

The FDA has cleared the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also known as the RemUnity system. The Food and Drug Administration (FDA) has cleared the Unity ...

Patients with pulmonary arterial hypertension will shortly have a more convenient way to treat their disease. United Therapeutics and DEKA Research & Development have received the Food and Drug ...

Innovation in drug-device combinations for administering Remodulin will likely help offset losses from generics, if approved. We believe both the already-approved Remunity pump and the Implantable ...

It took Novartis' Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension drug Remodulin, but last month, the company managed to do just that. Now, ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA ...

Fourth, our partnership with Smith Medical on a new ultra-smart Bluetooth connected subcutaneous and intravenous Remodulin pump. This device will be seamlessly integrated with the patient's smartphone ...

Branded drugmakers often take creative strategies to protect their meds from generic competition. In United Therapeutics' case, the lever for shielding Remodulin was an exclusive deal with a drug-pump ...

In a recent press release, Medtronic announced that it has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary ...